OPTN/SRTR 2023 Annual Data Report: Kidney

IF 8.2 2区 医学 Q1 SURGERY American Journal of Transplantation Pub Date : 2025-02-01 DOI:10.1016/j.ajt.2025.01.020
Krista L. Lentine , Jodi M. Smith , Grace R. Lyden , Jonathan M. Miller , Sarah E. Booker , Thomas G. Dolan , Kayla R. Temple , Samantha Weiss , Dzhuliyana Handarova , Ajay K. Israni , Jon J. Snyder
{"title":"OPTN/SRTR 2023 Annual Data Report: Kidney","authors":"Krista L. Lentine ,&nbsp;Jodi M. Smith ,&nbsp;Grace R. Lyden ,&nbsp;Jonathan M. Miller ,&nbsp;Sarah E. Booker ,&nbsp;Thomas G. Dolan ,&nbsp;Kayla R. Temple ,&nbsp;Samantha Weiss ,&nbsp;Dzhuliyana Handarova ,&nbsp;Ajay K. Israni ,&nbsp;Jon J. Snyder","doi":"10.1016/j.ajt.2025.01.020","DOIUrl":null,"url":null,"abstract":"<div><div>In 2023, the field of kidney transplantation faced both successes and challenges. A record 28,142 total kidney transplants were achieved in the United States, largely due to an increase in deceased donor kidney transplants (DDKTs). While the number of adult candidates listed for DDKT slightly increased, it remained below the level in 2019, with 11.4% of candidates waiting 5 years or more. Across racial and ethnic groups, Black adult candidates had the largest increase in DDKT rate in 2023, in parallel with the Organ Procurement and Transplantation Network policy to modify waiting time (implemented January 5, 2023). Following increases in death rates during the COVID-19 pandemic, pretransplant mortality declined in 2023 across various age, race and ethnicity, sex, and blood type categories, although mortality continued to vary substantially by donation service area. The rate of deceased donor kidneys that were recovered for transplant but not transplanted (nonuse) increased to a notable high of 27.9%, from 26.6% in 2022, with even higher rates for biopsied kidneys (41.4%), those from donors aged 65 years or older (72.2%), and kidneys with a kidney donor profile index of 85% or higher (72.5%). In contrast, nonuse of kidneys recovered from hepatitis C virus nucleic acid test–positive donors declined to 27.2% in 2023, from 43.0% in 2017, likely reflecting more common use of protocols incorporating direct-acting antiviral therapy. Disparities in access to living donor kidney transplant (LDKT) persist and particularly affect non-White and publicly insured patients. Delayed graft function has risen over the past decade, but appears to have plateaued, at 26.1% overall for adult recipients in 2023. Five-year graft survival rates were 90.0% for LDKT compared with 82.2% for DDKT in recipients aged 18-34 years, and 80.2% for LDKT versus 66.1% for DDKT in those aged 65 years or older.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 2","pages":"Pages S22-S137"},"PeriodicalIF":8.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Transplantation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1600613525000267","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

In 2023, the field of kidney transplantation faced both successes and challenges. A record 28,142 total kidney transplants were achieved in the United States, largely due to an increase in deceased donor kidney transplants (DDKTs). While the number of adult candidates listed for DDKT slightly increased, it remained below the level in 2019, with 11.4% of candidates waiting 5 years or more. Across racial and ethnic groups, Black adult candidates had the largest increase in DDKT rate in 2023, in parallel with the Organ Procurement and Transplantation Network policy to modify waiting time (implemented January 5, 2023). Following increases in death rates during the COVID-19 pandemic, pretransplant mortality declined in 2023 across various age, race and ethnicity, sex, and blood type categories, although mortality continued to vary substantially by donation service area. The rate of deceased donor kidneys that were recovered for transplant but not transplanted (nonuse) increased to a notable high of 27.9%, from 26.6% in 2022, with even higher rates for biopsied kidneys (41.4%), those from donors aged 65 years or older (72.2%), and kidneys with a kidney donor profile index of 85% or higher (72.5%). In contrast, nonuse of kidneys recovered from hepatitis C virus nucleic acid test–positive donors declined to 27.2% in 2023, from 43.0% in 2017, likely reflecting more common use of protocols incorporating direct-acting antiviral therapy. Disparities in access to living donor kidney transplant (LDKT) persist and particularly affect non-White and publicly insured patients. Delayed graft function has risen over the past decade, but appears to have plateaued, at 26.1% overall for adult recipients in 2023. Five-year graft survival rates were 90.0% for LDKT compared with 82.2% for DDKT in recipients aged 18-34 years, and 80.2% for LDKT versus 66.1% for DDKT in those aged 65 years or older.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
OPTN/SRTR 2023年度数据报告:肾脏
2023年,肾移植领域既面临成功,也面临挑战。在美国,肾脏移植总数达到了创纪录的28,142例,这在很大程度上是由于已故供体肾脏移植(DDKTs)的增加。虽然DDKT的成年候选人人数略有增加,但仍低于2019年的水平,11.4%的候选人等待5年或更长时间。在种族和民族群体中,黑人成年候选人在2023年的DDKT率增幅最大,与器官获取和移植网络政策同步,以修改等待时间(2023年1月5日实施)。在COVID-19大流行期间死亡率上升之后,2023年各种年龄、种族和民族、性别和血型类别的移植前死亡率下降,尽管死亡率继续因捐赠服务地区而有很大差异。用于移植但未移植(未使用)的已故供者肾脏的恢复率从2022年的26.6%增加到27.9%的显着高点,活检肾脏(41.4%),65岁及以上供者肾脏(72.2%)和肾脏供者特征指数为85%或更高的肾脏(72.5%)的比例更高。相比之下,从丙型肝炎病毒核酸检测呈阳性的供体中恢复的肾脏的不使用率从2017年的43.0%下降到2023年的27.2%,这可能反映了直接抗病毒治疗方案的更普遍使用。获得活体供体肾脏移植(LDKT)的差距持续存在,特别是影响非白人和公共保险患者。在过去十年中,延迟移植功能有所上升,但似乎已经趋于平稳,到2023年,成人受者的延迟移植功能总体为26.1%。在18-34岁的受者中,LDKT的5年生存率为90.0%,而DDKT的5年生存率为82.2%;在65岁及以上的受者中,LDKT的5年生存率为80.2%,DDKT的5年生存率为66.1%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
18.70
自引率
4.50%
发文量
346
审稿时长
26 days
期刊介绍: The American Journal of Transplantation is a leading journal in the field of transplantation. It serves as a forum for debate and reassessment, an agent of change, and a major platform for promoting understanding, improving results, and advancing science. Published monthly, it provides an essential resource for researchers and clinicians worldwide. The journal publishes original articles, case reports, invited reviews, letters to the editor, critical reviews, news features, consensus documents, and guidelines over 12 issues a year. It covers all major subject areas in transplantation, including thoracic (heart, lung), abdominal (kidney, liver, pancreas, islets), tissue and stem cell transplantation, organ and tissue donation and preservation, tissue injury, repair, inflammation, and aging, histocompatibility, drugs and pharmacology, graft survival, and prevention of graft dysfunction and failure. It also explores ethical and social issues in the field.
期刊最新文献
Reply to: HOPExt study: relevance of recipient factors and implications for future machine perfusion trials design Out-of-Sequence or Out of Options? Rethinking Liver Allocation in a Crisis of Confidence. Personal Viewpoint: Risk stratification and counseling of living kidney donor candidates with prediabetes. Reassessing the Evidence for Elevated dMMR Colorectal Cancer Risk After Kidney Transplantation. Anti-CMV immunotoxin during ex vivo machine perfusion: are we ready for CMV-negative transplantation?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1